TY - JOUR
T1 - Parkinson´s day-clinic
T2 - which patients should be selected and what services should be offered for successful therapy?
AU - Buhmann, C.
AU - Kalbe, E.
AU - Claus, I.
AU - Hilker-Roggendorf, R.
AU - Müller, T.
AU - Ip, C. W.
AU - Wüllner, U.
AU - Krüger, R.
N1 - Funding:
CB received a grant from the Hilde-Ulrichs-Stif-
tung, served as a consultant for Bial, Hormosan Pharma, Merz Phar-
maceuticals and Zambon, and received honoraria for scientific presen-
tations from AbbVie, Bial, Stada Pharma, TAD Pharma, UCB Pharma,
and Zambon. EK has received grants from the German Ministry of
Education and Research, General Joint Committee, Germany, the Ger-
man Parkinson Society, and STADAPHARM GmbH; honoraria from
AbbVie GmbH Germany; memodio GmbH Germany; license fees
from Prolog GmbH, Germany. EK is one of the authors of the cogni-
tive intervention series “NEUROvitalis” but receives no correspond-
ing honoraria. IC is receiving grants from Merz Pharmaceuticals,
served as a consultant for Abbvie, Stadapharm and Desitin, received
honoraria for scientific presentations and/or travel grants from Abbvie,
Stadapharm, Bial, Zambon and Merz Pharmaceuticals. RK is receiving
or has received research grants from the Fonds National de Recherche
(FNR) Luxembourg, Fondation Veuve-Metz-Tesch Luxembourg, the
Leir Foundation, the Michael J. Fox Foundation for Parkinsonʼs Re-
search (MJFF), the European Institute of Innovation and Technology
(EIT Health), the Innovative Medicines Initiative (IMI) of the Europe-
an Union and the European pharmaceutical industry, and the European
Union’s Horizon 2020 and Horizon Europe research and innovation
programs. RK received speaker’s honoraria and/or travel grants from
Abbvie, Bial, Desitin, Medtronic and Zambon. RK is participating or
has participated as PI or site-PI for industry sponsored clinical trials
without receiving personal honoraria.
Publisher Copyright:
© The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2025.
PY - 2025/4/29
Y1 - 2025/4/29
N2 - The demographic development and the advance of intensified yet time and personnel-intensive therapeutic options constitute increasing challenges for the care of people with advanced Parkinson’s disease (PD). Often, the multitude of motor and non-motor symptoms cannot be adequately addressed in an ambulatory setting The concept of a Parkinson’s day clinic has been put forward to meet the requirements for these patients who not necessarily require the full medical support of an inpatient treatment and was included into the Parkinson’s guidelines of the German Neurological Society as a novel and promising medical care model. While the guidelines put forward some recommendations as to which patients are most likely to benefit from treatment in a Parkinson’s day clinic, it has not yet been decided which infrastructural, operational, personnel and qualitative requirements such a setting should provide. Here we provide recommendations on the basis of an expert consensus as to which patients will particularly benefit from treatment in a Parkinson´s day clinic and which services such a day clinic should address in order to provide successful therapy. Furthermore we suggest a standard operating procedure (SOP) and we give examples of patients who are suitable for treatment in a Parkinson´s day clinic.
AB - The demographic development and the advance of intensified yet time and personnel-intensive therapeutic options constitute increasing challenges for the care of people with advanced Parkinson’s disease (PD). Often, the multitude of motor and non-motor symptoms cannot be adequately addressed in an ambulatory setting The concept of a Parkinson’s day clinic has been put forward to meet the requirements for these patients who not necessarily require the full medical support of an inpatient treatment and was included into the Parkinson’s guidelines of the German Neurological Society as a novel and promising medical care model. While the guidelines put forward some recommendations as to which patients are most likely to benefit from treatment in a Parkinson’s day clinic, it has not yet been decided which infrastructural, operational, personnel and qualitative requirements such a setting should provide. Here we provide recommendations on the basis of an expert consensus as to which patients will particularly benefit from treatment in a Parkinson´s day clinic and which services such a day clinic should address in order to provide successful therapy. Furthermore we suggest a standard operating procedure (SOP) and we give examples of patients who are suitable for treatment in a Parkinson´s day clinic.
KW - Concept
KW - Day-clinic
KW - Day-hospital
KW - Parkinson
KW - Requirements
UR - http://www.scopus.com/inward/record.url?scp=105004201360&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/40299066/
U2 - 10.1007/s00702-025-02923-1
DO - 10.1007/s00702-025-02923-1
M3 - Article
C2 - 40299066
AN - SCOPUS:105004201360
SN - 0300-9564
JO - Journal of Neural Transmission
JF - Journal of Neural Transmission
ER -